Science 3 min read

First HIV Immunotherapy Drug Passes Phase 1 Clinical Trial

vchal /

vchal /

Initial clinical trials of the first HIV immunotherapy drug has revealed that it is safe for human use.

Researchers from the University of North Carolina have successfully tested an HIV immunotherapy drug that they have developed, and the results revealed that the drug is safe for humans. The preliminary result from the Phase 1 clinical trial is a significant milestone for the team of researchers who won a $20 million USD grant to make their ideas a reality.

The hopeful HIV cure involves using adoptive cellular therapy to harness T cell responses. The researchers did this by harvesting T cells from a patient. The T cells are then grown in the lab to increase their numbers so they can be given back to the patient to boost their immune system and fight the disease.

“We found that this approach of re-educating the immune cells and reinfusing them was safe, which was the primary goal of the study. The data from this trial will continue to help us design improved immunotherapies against HIV,” David Margolis, co-senior author of the study, explained.

In their study published in the journal Molecular Therapy, the researchers expressed high hopes about the potentials of using immunotherapy in curing HIV positive patients without the risk of death.

“We think that we will be able to replicate the results of the Berlin patient, but that will take a while, on a step-by-step trajectory,” Margolis added.

Timothy Brown, the American famously known as the ‘Berlin patient’, is the only person to ever be cured of HIV. Brown was also diagnosed with leukemia and was later treated with a bone marrow transplant.

Brown was declared free of leukemia after receiving bone marrow from a donor who had genes resistant to HIV. Not only that, following the transplant, the doctors found no trace of HIV in Brown’s body. Brown made headlines worldwide, giving the medical community and HIV positive patients renewed hope of a possible cure.

However, attempts to replicate the treatment have, so far, been futile. It has spurred on other teams to continue the search for the miracle HIV cure, and this new study may just be that.

“This is a promising advancement for the field. The study did not cure HIV and should not be interpreted as doing so, but we also are very encouraged by the safety data, so it should not be considered discouraging either,” Julia Sung, first author of the study, said.

Do you believe that this new HIV immunotherapy drug is the miracle the medical community and patient needs to cure HIV?

First AI Web Content Optimization Platform Just for Writers

Found this article interesting?

Let Chelle Fuertes know how much you appreciate this article by clicking the heart icon and by sharing this article on social media.

Profile Image

Chelle Fuertes

Chelle is the Product Management Lead at INK. She's an experienced SEO professional as well as UX researcher and designer. She enjoys traveling and spending time anywhere near the sea with her family and friends.

Comments (0)
Most Recent most recent
share Scroll to top

Link Copied Successfully

Sign in

Sign in to access your personalized homepage, follow authors and topics you love, and clap for stories that matter to you.

Sign in with Google Sign in with Facebook

By using our site you agree to our privacy policy.